Literature DB >> 15931811

Intrapartum management of severe fetal airway obstruction.

Diego A Preciado1, Michael J Rutter, James M Greenberg, Ray Bahado-Singh, Donna Lambers, J Paul Willging.   

Abstract

OBJECTIVE: To review our experience with the planned intrapartum management of fetuses with suspected severe airway obstruction.
METHODS: Retrospective review of prenatal presentations, intrapartum airway procurement methods, outcomes, and complications.
RESULTS: All cases (N = 11) at our tertiary airway referral institution between 1995 and 2002 were reviewed. Obstruction was secondary to giant cervicofacial lymphangiomas (5), teratomas (2), epignathis (1), epulis (1), conjoined fetus (1), and tracheal foreign body (1). Elective cesarean delivery of the entire fetus was performed while maintaining fetal-placental circulation as long as possible. We found it necessary to deliver the entire fetus to improve airway exposure and decrease maternal hemorrhage. The airway was secured effectively in all cases.
CONCLUSIONS: Although full cesarean delivery of the fetus significantly reduces fetal-placental circulation times, in comparison with the formal ex utero intrapartum treatment (EXIT) procedure, airway access is improved, maternal complications may be decreased, and high airway procurement success is still safely achieved.

Entities:  

Mesh:

Year:  2004        PMID: 15931811     DOI: 10.2310/7070.2004.03084

Source DB:  PubMed          Journal:  J Otolaryngol        ISSN: 0381-6605


  2 in total

1.  Evidence for autosomal dominant inheritance in prenatally diagnosed CHAOS.

Authors:  Piet Vanhaesebrouck; Kris De Coen; Paul Defoort; Hubert Vermeersch; Geert Mortier; Linde Goossens; Koen Smets; Alexandra Zecic; Sabine Vandaele; Frans De Baets
Journal:  Eur J Pediatr       Date:  2006-04-27       Impact factor: 3.183

2.  Changes of laryngeal parameters during intrauterine life.

Authors:  Aleksandra Gawlikowska-Sroka; D Miklaszewska; E Dzieciolowska-Baran; E Kamienska; T Sroczynski; I Poziomkowska-Gesicka
Journal:  Eur J Med Res       Date:  2010-11-04       Impact factor: 2.175

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.